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Abstract 
Background. Accumulating evidence suggests that -synuclein aggregates, a defining pathology 
of Parkinson’s disease (PD), display cell-to-cell transmission. The initial -synuclein aggregation 
may start in autonomic nerve terminals years prior to appearance of motor symptoms, and 
subsequently spread via autonomic nerves to the spinal cord and brainstem. If this hypothesis is 
correct, patients with idiopathic REM sleep behaviour disorder (iRBD), a prodromal phenotype of 
PD with RBD and dementia with Lewy bodies, could display a pattern of pathology where the 
peripheral autonomic nervous system and locus coeruleus (LC) are affected ahead of the 
nigrostriatal dopamine system. We aimed to investigate function of sympathetic, parasympathetic, 
noradrenergic, and dopaminergic innervation in iRBD patients using multi-modality imaging. 
Methods. In this clinically prospective, case-control study, polysomnography-confirmed iRBD 
subjects without clinical signs of parkinsonism or dementia were recruited via advertisement and 
sleep clinics in Denmark. We used 11C-donepezil PET/CT to assess their cholinergic activity 
(parasympathetic) in the gut, 123I-MIBG scintigraphy to measure cardiac sympathetic function, 
neuromelanin-sensitive MRI to measure density of pigmented neurons of the LC, 11C-MeNER PET 
to assess noradrenergic transporter availability in terminals originating from the LC, and 18F-DOPA 
PET to assess nigrostriatal dopamine storage capacity. For each imaging modality, findings for 
iRBD subjects were compared to those of controls without neurological disorders or cognitive 
impairment and to symptomatic PD patients. Imaging data were interrogated with one-way 
ANOVAs corrected for multiple comparisons. 
Findings. Twenty two iRBD patients were consecutively included between June 2016 and Dec 
2017. Compared to healthy controls, the iRBD patients showed significant decreases in colonic 
11C-donepezil uptake (-0·322 (CI-0·112; -0·531); p=0·0020), 123I-MIBG heart-mediastinum ratios 
(-0·508 (CI:-0·353; -0·664); p<0·0001), neuromelanin-MRI LC/pons ratios (-0·059 (CI:-0·019; -
0·099); p=0·0028), 11C-MeNER binding potential in the left thalamus (-0·080 (CI:-0·010; -0·150) 
p=0·023), and putaminal 18F-DOPA Ki (-0·0023 (CI:-0·0009; -0·0037); p=0·0013). The iRBD and 
PD groups had similar gut 11C-donepezil (p=0·39), heart 123I-MIBG (p>0·99), neuromelanin-MRI 
(P=0·96), and brain 11C-MeNER signals (P=0·66). In contrast, while 71% of iRBD cases had 
normal putamen 18F-FDOPA Ki values, this was significantly reduced in all the PD patients (iRBD 
vs. PD: p<0·0001).  
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Interpretation.  
Patients with iRBD displayed similar peripheral dysfunction to symptomatic PD in their 
sympathetic and parasympathetic nervous systems, and a similar loss of pigmented cells of the LC. 
In contrast to PD, 71% of iRBD cases had normal putaminal dopaminergic storage capacity. As 
iRBD can progress to PD with RBD or DLB, the peripheral dysfunction present in the absence of 
dopamine terminal damage supports the hypothesis that -synuclein pathology in PD targets 
peripheral autonomic nerves ahead of involving nigral cells in the midbrain. 
Funding. Lundbeck Foundation. Jascha Foundation. Swiss National foundation. 
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Research in context  
Background 
   Prospective studies have shown that most cases of idiopathic rapid-eye-movement sleep 
behaviour disorder (iRBD) represents a prodromal phenotype of the synucleinopathies Parkinson’s 
disease (PD) or dementia with Lewy bodies (DLB). We searched PubMed in all languages on 
December 20, 2017 using the keywords “Parkinson disease”, “Lewy body disease”, “REM sleep 
behaviour disorder”, “positron-emission tomography”, “tomography emission-computed single-
photon”, “magnetic resonance imaging”, “dual-hit hypothesis”, “alpha-synuclein”. We found no 
previous in vivo studies which had used multimodal imaging to comprehensively assess the levels 
of dysfunction in the autonomic nervous system, locus coeruleus, and substantia nigra of patients 
with iRBD or genetically susceptible prodromal PD cohorts.  
   Accumulating evidence suggests that the defining pathology of PD, aggregated -synuclein, is 
capable of cell-to-cell transmission. It has been hypothesised that the initial misfolding and 
aggregation may occur in the olfactory bulb and autonomic nerve terminals, and then spread 
centripetally to the brain. This view is supported by evidence that peripheral-to-central spreading 
of -synuclein can be induced in animal models, by epidemiological evidence that total vagotomy 
protects against PD, and the finding of pathological -synuclein aggregates in the gut of PD 
patients years prior to their diagnosis.  
Added value of this study  
To our knowledge, we present the most comprehensive imaging study to date of iRBD, potentially 
a prodromal PD+RBD/DLB patient cohort. We demonstrate convincing sympathetic and 
parasympathetic dysfunction in iRBD patients equivalent to that seen in diagnosed PD patients, 
along with similar loss of pigmented locus coeruleus cells and thalamic noradrenaline transporters. 
In contrast to PD patients, 71% of our iRBD cases had normal 18F-FDOPA uptake in their putamen.  
Implications  
Our imaging findings support the hypothesis that those PD cases with RBD have early dysfunction 
in their peripheral autonomic system and locus coeruleus prior to involvement of their nigral 
dopamine system by -synuclein pathology.  
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Introduction 
   The pathological hallmarks of Parkinson’s disease (PD) are progressive loss of nigrostriatal 
dopaminergic innervation and the presence of abnormal -synuclein (-syn) aggregates in 
vulnerable neuron populations. Accumulating evidence suggests that misfolded -syn protein can 
act as a template, encouraging further -syn to misfold with formation of insoluble filamentous 
inclusions which are capable of cell-to-cell transmission through interconnected neuronal 
pathways1. In most cases of PD, the distribution of brain -syn inclusions displays a characteristic 
caudo-rostral gradient with the lower brainstem nuclei becoming first involved2. It has been 
hypothesized that -syn aggregates initially form in the olfactory bulb and nerve terminals of the 
gastrointestinal lining. Subsequently, the pathology spreads via autonomic nerves to the dorsal 
motor nucleus of the vagus (DMV) and intermediolateral cell columns (IML) of the sympathetic 
system3,4. This hypothesis is supported by animal studies showing that peripheral-to-central 
spreading of -syn aggregates through autonomic nerves can be induced5, epidemiological 
evidence that truncal vagotomy is protective against PD6,7, and the finding of -syn inclusions in 
gastrointestinal nerve fibres many years prior to clinical PD diagnosis8. However, human autopsies 
have failed to support the view that PD is initiated in the gut9. Currently, cell-to-cell transmission 
of aggregated -syn and the peripheral-onset hypothesis are intensely debated topics in PD 
research4,10,11. 
   In the present study, we performed comprehensive multimodal imaging of patients with 
idiopathic rapid-eye-movement sleep behaviour disorder (iRBD). Most iRBD cases will eventually 
develop a synucleinopathy – PD with RBD, dementia with Lewy bodies (DLB), or rarely, multiple 
system atrophy (MSA)12,13. iRBD is believed to arise from degeneration of the pontine nuclei, 
including the magnocellular reticular formation, sublaterodorsal nucleus, and peri-coeruleus 
complex2,14. These structures are situated close to the locus coeruleus (LC). Importantly, 
pathological phosphorylated -syn inclusions have been detected in the colon and sympathetic 
chain in iRBD patients15,16. If the peripheral-to-central spreading hypothesis of -syn is correct, 
we predicted that a significant fraction of iRBD cases would display dysfunction of peripheral 
autonomic nerves equivalent to that seen in symptomatic PD, and that the LC could be involved 
ahead of the dopamine cells in the substantia nigra compacta which would be relatively spared as 
iRBD patients do not exhibit overt parkinsonism. We used 11C-donepezil PET-CT to assess 
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cholinergic (including parasympathetic) activity of the gut17,18, 123I-MIBG scintigraphy to measure 
integrity of sympathetic cardiac innervation19, neuromelanin-sensitive MRI to measure the density 
of pigmented cell bodies of the LC20,21, 11C-MeNER PET to assess thalamic noradrenaline 
transporter binding in the terminals of LC projections21,22, and finally 18F-DOPA PET to assess 
nigrostriatal dopamine storage capacity23.  
 
Methods 
 
Study design and participants 
   The study was conducted between June 3rd, 2016, and December 19th, 2017. We recruited 
consecutively 22 iRBD patients with polysomnographic confirmation (Supplementary methods). 
Inclusion criteria: iRBD diagnosis according to International Classification of Sleep Disorders III, 
age 50-85 years. Exclusion criteria: A clinical diagnosis of PD or DLB according to consensus 
criteria24,25, a Montreal Cognitive assessment (MoCA) score <23, or the presence of psychiatric 
disorders, medication interfering with the noradrenergic system, cholinesterase inhibitors, diabetes, 
neuropathies, heart- or kidney failure, current or previous cancer and/or major surgery on 
abdominal organs, inflammatory bowel disease.  
   Table 1 summarizes clinical and demographic data of the iRBD patients and imaging-modality 
specific PD and control groups who were scanned with identical methodologies. More clinical 
information is listed in Supplementary table 1. Much of the reference imaging data has been 
published previously17,21,23. The study was approved by the Science Ethical Committee of the 
Central Denmark Region (case nr. 1-10-72-160-16). All subjects provided informed written 
consent according to the Declaration of Helsinki. 
 
Imaging 
   The five imaging modalities and their relationship to neuropathological Braak stages I-III of -
syn aggregation in PD are represented in Figure 1. The sympathetic autonomic nuclei are not part 
of the original Braak PD staging scheme2, but are included here in stage I as the IML and 
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paravertebral sympathetic chain are nearly always involved in cases with incidental Lewy body 
disease26,27.  
   All subjects were scanned on either 3T Siemens TRIO or 3T Siemens SKYRA MR systems; 
protocols included T1 and fluid-attenuated inversion recovery images. Neuromelanin sensitive 
images were obtained in a subset of 11 iRBD patients, as previously described21. Using a volume 
of interest (VOI) approach, LC/pons ratios were calculated (Supplementary methods). All MRI 
and PET analyses were performed in PMOD 3·6 (PMOD, Zürich, Switzerland).  
     11C-donepezil PET/CT was performed, as previously described17. Subjects fasted for at least 8 
hours and abstained from drinking 4 hours before PET. Forty-five minutes after injection of 500 
MBq 11C-donepezil, static PET images were performed in 3D-mode with the abdominal organs in 
field-of-view. High-resolution CT with contrast-enhancement was performed immediately prior to 
PET. Body-weight corrected standard uptake values (SUV) were calculated: SUV = concentration 
(kBq/mL)/[injected dose (kBq)/body weight (g)]. VOIs were defined on the small and large 
intestine as previously described17. Intra-luminal water content was excluded from the small 
intestine and SUVs were extracted from the VOIs. Small intestine and colon SUVs were adjusted 
for volume to avoid underestimating the PET signal in PD and iRBD patients17. 
   123I-MIBG scintigraphy was performed using a dual-head gamma camera (Siemens Symbia 
SPECT/CT, Erlangen, Germany) with a low-energy high-resolution collimator. 15-minute images 
of the thorax were obtained 15 minutes (early) and 3·5 hours (late) after injection of 110 MBq 123I-
MIBG. Regions of interest were defined on the heart and mediastinum. Mean heart-uptake /mean 
mediastinum-uptake (H/M) ratios were calculated on early and late images, and washout rates 
(WR) were calculated as H/Mlate – H/Mearly. 
   18F-DOPA and 11C-MeNER PET was performed, as previously described21,23. One hour before 
18F-FDOPA injection, 150 mg of carbidopa was administered orally. After a transmission scan, 
tracer doses of 120 MBq 18F-DOPA or 550 MBq 11C-MeNER were injected intravenously and 
dynamic PET (FDOPA 94·5 min; MeNER 90 min) acquired in list mode on an ECAT high-
resolution research tomograph (HRRT; Siemens/CTI, Knoxville, TN). PET data were reconstructed 
using a 3D-OSEM algorithm yielding dynamic PET data volumes (Supplementary methods). 
PET images were normalized to MNI space with rigid matching of subject’s PET to the anatomical 
MRI, and MRI segmentation using the built-in Hammers N30R83 atlas. 
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Table 1. Demographic and clinical data of the iRBD patients, and the PD and healthy control (HC) reference groups.  
 
  Sex, m/f Age, y DD, y UPDRS 
H&Y 
I/II/III/IV MMSE MOCA OH, y/n Olfaction NMSQuest 
 
Donepezil 
 
RBD 16/4 68±9 - 1 (0-5) - - 27 (23-30) 7/13 6 (2-13) 7 (2-15) 
 
PD 10/8 62±8 1·7±0·6 19 (6-26) 0/14/2/0 29 (27-30) - - 6 (1-14) 7 (2-14) 
 
HC 9/7 65±6 - - - 29 (24-30) - - 11 (6-13) 1 (0-7) 
 
MIBG                   
 
RBD 18/4 68±9 - 1 (0-5) - - 27 (23-30) 7/15 6 (2-13) 7 (2-15) 
 
PD 12/5 65±8 9.9±2.8 43 (25-52) 0/10/7/0 29 (24-30) - 2/13 7 (2-11) - 
 
HC 4/6 63±9 - - - 30 (27-30) - 0/6 11 (8-13) - 
 
Neuromelanin 
 
RBD 9/2 67±7 - 1 (0-5) - - 28 (24-30) 4/7 6 (3-9) 6 (3-15) 
 
PD 21/8 67±9 6·2±4·2 37 (11-51) 2/26/1/0 - 26 (23-30) 10/16 6 (2-14) 7 (1-19) 
 
HC 12/5 68±7 - - - - 29 (27-30) 0/10 12 (6-15) 2 (0-14) 
 
MeNER 
 
RBD 14/3 66±8 - 1 (0-5) - - 28 (24-30) 5/12 6 (2-13) 6 (2-15) 
 
PD 22/8 67±9 6·4±4·3 37 (11-62) 2/26/1/1 - 27 (23-30) 10/16 6 (2-14) 7 (1-19) 
 
HC 9/2 67±6 - - - - 28 (27-30) 0/10 12 (6-13) 2 (0-7) 
 
FDOPA 
 
RBD 17/4 68±9 - 1 (0-5) - - 27 (23-30) 7/14 6 (2-13) 7 (2-15) 
 
PD 8/2 64±9 10·6±3·2 44 (29-52) 0/5/5/0 29 (24-30) - 1/8 7 (2-10) - 
 
HC 14/4 64±6 - - - 30 (27-30) - 0/6 12 (6-15) 2 (0-4) 
 
 
Data presented as mean±SD or median (range). Orthostatic hypotension (OH) measurements were only available for a subset of the reference 
subjects. [DD=disease duration of PD. H&Y=Hoehn & Yahr stage. MMSE=mini-mental state examination. MoCA=Montreal cognitive 
assessment. UPDRS=Unified PD Rating scale – part III.] 
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Figure 1. The five imaging modalities and their relationship to Braak stage structures involved in PD are denoted by 
roman numerals. I. 11C-donepezil PET signal of the intestine is a marker of decreased acetylcholine esterase activity, 
reflecting cholinergic innervation including parasympathetic innervation from the dorsal motor nucleus of the vagus 
(DMV). Arrows indicate the small intestine. 123I-MIBG is a validated tracer of sympathetic cardiac innervation II. 11C-
MeNER measures the availability of noradrenaline transporters in terminals originating from the locus coeruleus (LC). 
The integrity of the pigmented cell bodies of the LC is estimated by neuromelanin-sensitive MRI (arrows). III. Striatal 
dopamine storage capacity of projections from the substantia nigra (SN) is measured with 18F-DOPA PET. 
  For the FDOPA analysis, time-activity curves were extracted from template VOIs placed in the 
putamen and occipital cortex. The Gjedde-Patlak graphical approach was applied to estimate 
specific FDOPA uptake (Ki) in putamen using occipital cortex as a reference28. The lowest of 
left/right putamen Ki values was always used for analyses. 11C-MeNER uptake was investigated in 
the thalamus and red nucleus, since previous 11C-MeNER PET studies showed robust PD vs. 
healthy control differences in these structures21,22. Template VOIs were defined in the thalamus, 
red nucleus, and occipital cortex (reference region), as previously described21. PET images were 
smoothed with a 4mm Gaussian filter and time activity curves extracted from VOIs for calculation 
of binding potentials relative to non-displaceable binding (BPND) using the simplified reference 
tissue model 2 (SRTM2).  
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Other assessments 
   Autonomic and non-motor symptoms were assessed with the non-motor symptoms questionnaire 
(NMSQuest)29, constipation with ROME III diagnostic criteria, motor symptoms with the MDS 
Unified PD Rating Scale part III (MDS-UPDRS III), and RBD symptoms with the RBD symptom 
questionnaire30. Cognitive status of iRBD patients was evaluated with the MoCA battery, whereas 
some of the control and PD comparator groups had been assessed with the Mini mental state 
examination (MMSE). After 15 minutes of supine rest, blood pressure was measured for three 
consecutive minutes after tilting. Orthostatic hypotension was defined as systolic pressure drop of 
20 mmHg or diastolic pressure drop of 10 mmHg. Olfaction was tested with the 16-item Sniffin’ 
Sticks identification battery.  
 
Statistical analyses 
   Statistical analyses were performed with Stata 14·2 and Graphpad PRISM 6. Normality of data 
was assessed with Shapiro-Wilk tests and Q-Q plots. Data are presented as mean±SD or median 
(range). Grubbs’ test was used to identify statistical outliers. Demographic and clinical data were 
interrogated using ANOVA, Kruskal-Wallis, and chi-squared tests as appropriate. Group 
comparisons of imaging data were performed with one-way ANOVA. The iRBD group was 
subsequently compared to the control and PD groups applying Dunnett’s correction for multiple 
comparisons. Associations between imaging data and clinical data were investigated with Pearson 
correlation or Spearman Rank correlation for continuous and categorical data. Significance level 
was set at p <0·05.  
Pathology index 
   To assess the degree to which iRBD subjects had reached “fully developed PD-level pathology” 
within each neuronal system, we converted the iRBD imaging data to a “PD pathology index”, by 
defining the corresponding healthy control mean as 0% and the PD mean as 100%. Resulting 
pathology indices were compared to published data from previous 123I-MIBG studies19,31 and 123I-
FP-CIT dopamine transporter studies of iRBD patients32,33, where controls and PD patient 
comparator data were presented.  
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Role of the funding source 
The funder of the study had no role in the study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the data in 
the study and had final responsibility for the decision to submit for publication.  
 
Results 
 
Clinical and demographic data 
   The iRBD group was 6 years older than the PD comparator group for 11C-donepezil PET 
(p=0·04), and the male/female ratio across the three 123I-MIBG subject groups was unmatched 
(p=0·059). There were no other significant differences in age or sex-distribution between the iRBD 
and comparator PD and control groups. Self-reported duration of RBD symptoms in the iRBD 
group was 6·3±5·6 years. The iRBD patients showed similar rates of hyposmia, orthostatic 
hypotension, and non-motor symptoms compared to all PD reference groups. Twenty of 22 (91%) 
iRBD patients were hyposmic. Two iRBD cases had MoCA scores of 23 and 24, while the 
remaining 20 subjects fell in the 25-30 range. These data are summarized in Table 1. 
 
Imaging data 
   Images from the five modalities are presented in Figure 2. Due to logistical challenges and 
technical failures, there were a few missing scans in the study. All 22 iRBD patients underwent 
MIBG scintigraphy, 21 had FDOPA PET, 20 donepezil PET, and 17 MeNER PET. Only 11 iRBD 
patients had neuromelanin-sensitive MRI. See Table 1 for exact numbers of subjects within each 
imaging modality. The median time lag from the first to last imaging session in the iRBD cohort 
was 92 days (range 7-265).  
   11C-donepezil PET. Significant between-group differences in 11C-donepezil uptake were seen in 
the small intestine (p=0·004, ANOVA, Figure 3A), and the colon (p=0·004, ANOVA, Figure 3B). 
Compared to healthy controls, iRBD patients displayed significantly lower uptake in the small 
intestine (p=0·0018) and colon (p=0·0020). Mean small intestine and colon values in the iRBD 
group were similar to PD patients (small intestine p=0·348, colon p=0·388). There was no 
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significant correlation between colon 11C-donepezil SUV and severity of constipation ROME 
(questions 9-15) ratings (p=0·42).  
 
 
 
 
 
 
 
 
Figure 2. Representative images from 
healthy controls (HC), iRBD, and PD 
patients with the five imaging modalities. 
Individual cases are representative of the 
group mean within the respective groups. 
A. 11C-donepezil PET/CT. Note lower 
donepezil uptake in the colon in iRBD 
and PD. Arrows denote transverse colon. 
B. 123I-MIBG scintigraphy of the heart 
(arrow). Note completely absent heart 
uptake in iRBD and PD. C. 
Neuromelanin (NM) MRI of locus 
coeruleus (arrows). Note lower locus 
coeruleus signal in iRBD and PD. D. 11C-
MeNER PET. Thalamic MeNER binding 
potential (BPND), shown by arrows, is 
decreased in iRBD and PD. E. 18F-DOPA 
PET. Putamen FDOPA signal (arrows) is 
mildly decreased in some iRBD cases, 
but markedly decreased in PD. 
 
  
  123I-MIBG scintigraphy. Highly significant between-group differences were seen in the late-image 
mean H/M ratios (p<0·0001, ANOVA, Figure 3C) and also in the MIBG WR (p<0·0001, 
ANOVA, Figure 3D). Compared to controls, the iRBD group showed significantly lower H/M 
ratios (p<0·0001) and WR (p<0·0001). No mean difference was seen between the iRBD and PD 
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groups (p>0·21). Using a cut-off criterion of “>2 SD below control mean” to define a pathological 
MIBG scan, 18 of 22 (82%) iRBD patients had pathological H/M ratios, and 20 of 22 (91%) iRBD 
had pathological WR rates. No significant correlations were seen between systolic or diastolic 
blood pressure drop and the H/M ratios or WR values (p>0·25).  
 
 
Figure 3. A-B. The volume-corrected 11C-donepezil standard uptake values (SUV) in the small intestine (A) and colon 
(B) of healthy controls (HC), iRBD, and PD patients. The colon was impossible to define in one HC, leaving only 15 
HC with colon values. C. Heart/mediastinum (H/M) ratio on the late 123I-MIBG images. D. Wash out values of MIBG 
from the early (15 min) to late image (3·5 h). [Solid lines denote group means. Dotted lines denote -1 and -2 SD below 
control mean].  
 
 
 
Figure 4. A. The MRI neuromelanin LC/pons ratio in healthy controls (HC), iRBD, and PD patients. B-C. The 11C-
MeNER PET binding potential (BPND) in the thalamus (Th) and nucleus ruber (Ru). C. The minimum (left or right) 
18F-DOPA Ki value in the putamen. [Solid lines denote group means. Dotted lines denote -1 and -2 SD below control 
mean]. 
 
Neuromelanin MRI. Highly significant differences were seen between the groups in neuromelanin 
LC/pons ratios (p=0·0004, ANOVA, Figure 4A). iRBD patients displayed significantly lower 
LC/pons ratios compared to the controls (p=0·0028) but similar to those of PD patients (p=0·96).  
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   11C-MeNER PET. An overall difference in thalamic 11C-MeNER BPND was seen across the groups 
with reduced mean uptake evident in both iRBD and PD groups (p=0·017, ANOVA, Figure 4B). 
No significant differences were seen when comparing mean BPND in the iRBD group directly with 
the healthy controls (p=0·095) or PD patients (p=0·56). A post hoc analysis of the left and right 
BPND values individually disclosed a significant reduction in the left thalamic 
11C-MeNER in the 
iRBD group compared to controls (p=0·023, Supplementary Figure 1). The 11C-MeNER BPND 
of the red nucleus also differed significantly across the three groups with reductions evident in 
iRBD and PD (p=0·033, ANOVA, Figure 4C), but no significant differences were seen when 
comparing the iRBD group with the healthy controls (p=0·103) or PD patients (p=0·74). 
   18F-DOPA PET. Highly significant between-group differences were seen in putamen FDOPA Ki 
values (p<0·0001, ANOVA; Figure 4D). When using a “>2 SD below control mean” criterion of 
pathology, 6 of 21 (29%) iRBD patients had pathologically reduced putamen FDOPA uptake. In 
contrast, all PD patients had pathological FDOPA PET, and a highly significant difference was 
seen in mean FDOPA Ki values between iRBD and PD groups (p<0.0001). 
 
 
Supplementary Figure 1. The 11C-MeNER PET binding potential (BPND) in the left (A) and right (B) thalamus of 
healthy controls (HC), iRBD, and PD patients. An overall difference in thalamic 11C-MeNER BPND was seen between 
the groups in the left thalamus (p=0·004, A), and post-ANOVA comparison of the iRBD to control group showed that 
the 11C-MeNER BPND reduction was significant in the left thalamus (p=0·023). Dotted lines denote -1 and -2 SD below 
control mean. 
 
Pathology index 
   Figure 5 depicts the pathology indices across the five imaging modalities. iRBD patients 
exhibited dysfunction equivalent to PD patients on 11C-donepezil PET, 123I-MIBG scintigraphy, 
and neuromelanin MRI measures. The index for thalamic noradrenergic transporter availability 
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with 11C-MeNER data was 73% but only 21% for putamen dopamine storage capacity measured 
with 18F-DOPA PET. Pathology indices from previous 123I-MIBG and dopamine transporter 
SPECT studies are shown for comparison (depicted with grey circles in Figure 5)19,31-33. 
Importantly, the iRBD patients showed extreme denervation of both the sympathetic and 
parasympathetic nervous systems (i.e. pathology indices >100%) compared to groups of mixed 
RBD-positive/negative early-stage PD patients. In contrast, the pathology indices of presynaptic 
dopaminergic imaging markers were 21-36%. More details are available in Supplementary table 
2. 
 
Figure 5. The figure shows pathology indices (mean±SEM) of the present iRBD imaging data (black circles) listed 
according to PD Braak stage structures. For each imaging modality the healthy control (C) average is set at 0% and 
PD average at 100%. Grey circles show pathology indices from two previous MIBG studies19,31 (a & b), and two 
dopamine transporter SPECT studies32,33 (c & d). The four grey points in b show the MIBG pathology index of iRBD 
patients compared to H&Y stage I through IV PD patients (roman numerals: I, II, III, IV). Note that the H&Y I index 
was actually 300% (denoted by * and up-arrow). That particular MIBG study demonstrated that iRBD patients show 
more severe cardiac sympathetic denervation than H&Y I-II PD patients (MIBG index >100%). Similarly, our iRBD 
group showed a donepezil PET index of 157% when compared to our early stage PD patients. In one dopamine 
transporter SPECT studies, iRBD patients were compared to de novo H&Y I patients (c), and in another iRBD cases 
were compared to PD patients with and without RBD (depicted with + and - RBD). [DON: donepezil colon values, 
NM: neuromelanin MRI] 
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Discussion 
   The “peripheral-onset” of PD  hypothesis posits that formation of abnormal -syn aggregates 
first occurs in nerve terminals of the olfactory, enteric, and autonomic nervous system. The 
aggregates then spread by retrograde axonal transport to the medullary DMV and spinal IML3. 
Here, we have demonstrated peripheral dysfunction at a level seen in established PD level in our 
iRBD patients who are likely to represent prodromal PD or DLB. Our findings do not prove that 
-syn misfolding is initiated peripherally by neurotropic pathogens, but are compatible with this 
view. Our findings argue against an isolated olfactory entry site of pathogens in PD11,34 as this 
would be difficult to reconcile with our observed cardiac and intestinal dysfunction and 
concomitant sparing of the nigra in iRBD. 
   11C-donepezil PET is not a specific marker of parasympathetic innervation, but measures 
acetylcholinesterase activity in both enteric neurons and parasympathetic synapses. However, 
pathology studies have not shown an appreciable loss of enteric neurons in PD, whereas damage 
to the DMV and parasympathetic sacral plexus is common. The most parsimonious explanation of 
decreased gastrointestinal 11C-donepezil signal is, therefore, loss of parasympathetic cholinergic 
terminals18. Whatever is responsible for the reduced 11C-donepezil signal in iRBD, this pathology 
appears to be fully developed by the prodromal stage of PD with RBD.  
   Nearly all our iRBD patients had pathological MIBG heart scans, in accordance with two 
previous, smaller iRBD studies19,31. Taken together, the available data show that approximately 
90% of iRBD patients have profound cardiac sympathetic denervation. We saw no correlations 
between MIBG signals and severity of orthostatic hypotension in iRBD; this is also the case in 
PD35. Interestingly, 40-50% of H&Y stage I PD patients have normal MIBG scans, but by stage 
H&Y III nearly all have pathological MIBG31. In the light of our MIBG results in iRBD, it is 
possible that those early-stage PD patients with normal MIBG scans are predominantly RBD-
negative36,37. We propose that the prodromal RBD phenotype of PD is characterized by early, 
severe pathology in the autonomic nervous system whereas RBD-negative early PD patients are 
less susceptible. This interpretation is supported by a previous MIBG report, which compared 
iRBD to PD patients across H&Y stages I through V31. These authors found MIBG pathology 
indices in iRBD of 300% (compared to H&Y I PD), 127% (H&Y II), 110% (H&Y III), and 102% 
(H&Y IV) (grey inserts in Figure 5). 
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   The iRBD group displayed a similar reduction in LC neuromelanin signal to our diagnosed PD 
patients. The PD comparator group comprised 15 polysomnography-verified RBD-positive and 14 
RBD-negative patients21. Our iRBD patients displayed a larger mean reduction in LC neuromelanin 
signal than the RBD-negative PD sub-group, although the difference was non-significant 
(Supplementary Figure 2)21. These observations are in line with previous studies of iRBD and 
PD20,38 and reinforce the conclusion that iRBD patients exhibit a more profound loss of LC 
neuromelanin than diagnosed PD patients without RBD. Damage to pontine nuclei, including 
sublaterodorsal nucleus and peri-coeruleus complex, is thought to be responsible for generating the 
RBD phenotype14. 
 
 
Supplementary Figure 2. The MRI neuromelanin LC/pons ratio in healthy controls (HC), iRBD, and PD patients 
with and without RBD. No significant differences were seen between iRBD and either PD group (iRBD vs. PD-RBD: 
p=0·344, iRBD vs. PD+RBD: p=0·662). However, the iRBD group displayed significantly lower values than the HC 
group (p=0·004). [Dotted line denotes 1 SD below control mean]. 
 
   11C-MeNER is a reboxetine analogue that binds specifically to noradrenaline transporters. Two 
recent studies have reported reduced 11C-MeNER binding in the red nucleus and thalamus of PD 
patients compared to controls21,22. Our iRBD patients had lower mean 11C-MeNER binding 
bilaterally in the thalamus and red nucleus than healthy controls but the reduction only reached 
significance in the left thalamus after a post hoc analysis (Supplementary Figure 1). Sommerauer 
et al. have previously reported that RBD-positive PD patients showed significant reductions in 
thalamic 11C-MeNER BPND, whereas RBD-negative PD patients did not. Our findings suggest that 
noradrenergic terminal loss is less pronounced in iRBD compared to PD patients with RBD. 11C-
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MeNER gives a low specific signal, so our study may well have lacked the power to detect 
bilaterally significant thalamic 11C-MeNER reductions with this intrinsically noisy tracer. 
   29% of our iRBD patients exhibited decreased putaminal FDOPA uptake in line with previous 
dopamine transporter imaging studies39,40. Our PD comparator group for FDOPA had established 
disability (Table 1) so severe nigrostriatal dopaminergic deficits would be expected (Figure 4D). 
The use of this PD group as a comparator resulted in a low FDOPA pathology index for the iRBD 
patients (21%) which could have been higher if iRBD had been compared with newly diagnosed 
PD cases. FDOPA PET is a marker of aromatic L-amino acid decarboxylase and this becomes up-
regulated in remaining terminals during the early stages of nigrostriatal degeneration41. Such 
upregulation could mask early dopaminergic dysfunction in iRBD when FDOPA PET is used as 
an imaging biomarker. Nevertheless, normal presynaptic dopamine imaging is considered an 
exclusion criterion for a PD diagnosis24. Since 71% of our iRBD subjects had normal putamen 
FDOPA uptake, we conclude that the dopaminergic system is considerably less affected in iRBD 
compared to the dusfunction of the autonomic nervous system and the LC. 
   We emphasize that our iRBD findings may only represent a valid prodrome of PD patients with 
additional RBD. It is accepted that RBD is associated with a more aggressive PD phenotype which 
shows  more widespread -syn deposition affecting most brain regions42, and faster progression of 
motor and non-motor symptoms43. We have demonstrated that the level of dysfunction in the 
autonomic nervous system of iRBD patients equals, and at times exceeds, that seen in unselected 
PD patients. Based on its pattern of autonomic and LC involvement, we hypothesize that non-
cognitively impaired iRBD parallels the Braak stage 2 PD distribution of Lewy pathology2. We 
speculate that this supports the view that, during the prodromal phase of PD or DLB with RBD, 
the -syn pathology responsible originates in peripheral autonomic/enteric nerve terminals. In 
contrast, RBD-negative early-stage PD patients may have a more benign phenotype where -syn 
pathology is primarily initiated within the CNS  and olfactory bulb. This hypothesis is speculative, 
but would explain why not all PD patients show a Braak-like distribution of -syn pathology at 
post-mortem  - 20% of cases have no pathology in the DMV11. 
   The dual-hit hypothesis is based on post-mortem Braak staging of PD brains2, however, DLB 
cases can exhibit alternative distributions of -syn pathology44. Our choice to study iRBD as a 
prodrome of PD can be criticized as ~50% of iRBD subjects will convert to DLB12,13. Despite this 
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caveat, our findings strongly suggest that iRBD represents a prodrome of both DLB and PD with 
RBD  and these patients are similar with respect to having early peripheral autonomic and LC 
dysfunction. We will follow-up our iRBD cases to determine whether those patients with a final 
PD+RBD diagnosis show more extensive peripheral dysfunction than the DLB converters. Finally, 
we propose that MIBG scintigraphy may be useful for predicting which iRBD cases will progress 
to clinical MSA as cardiac sympathetic innervation is preserved in this synucleinopathy35. We 
speculate that those iRBD cases with normal MIBG scans have a higher probability of representing 
prodromal MSA. This assertion needs confirmation in future studies.   
   The pattern of neuronal cell loss seen in PD does not parallel the severity of Lewy pathology and 
it has been suggested that regional or cell-related factors could be responsible for this9,11. Our 
findings are relevant to this discussion, since we primarily used markers of nerve terminal function, 
not cell body loss. -syn is a synaptic protein and its initial aggregation is thought to take place in 
neuronal terminals1. Studies have shown a more dramatic loss of nerve terminals compared to cell 
bodies across several neurotransmitter systems in PD35,45. This implies that neurons containing 
Lewy pathology will be most dysfunctional at a synaptic level, while their cell bodies may remain 
intact. Our results in iRBD show a pattern of neuronal terminal damage that parallels Braak stage 
2 of Lewy body pathology although cell body loss measured in post-mortem studies of early PD 
patients does not follow Braak -syn staging. The fact that some neurons containing -syn 
aggregates are more resistant to apoptosis than others  is not against the hypothesis that -syn 
aggregates can be transmitted through inter-connected neuronal networks, nor that the initial -syn 
aggregation may first occur in peripheral nerve terminals in some individuals. 
   This study has several limitations: First, we used different groups of healthy controls and PD 
patients as comparators when analysing iRBD imaging findings. This was to limit levels of 
radiation exposure to healthy and PD subjects and maintain scan tolerance as far as possible in our 
complex PET/MRI programme. However, except for minor differences in age distribution of the 
11C-donepezil groups and an unmatched male/female ratio in the 123I-MIBG data, all HC and PD 
reference groups were reasonably comparable to the iRBD patients in terms of demographic 
findings. Second, we included both early-stage and later-stage PD comparator groups. Thus, our 
pathology index of iRBD relative to PD for different imaging biomarkers (Figure 5) must be 
interpreted with caution. The most important finding is that the iRBD cases showed peripheral 
cholinergic and noradrenergic dysfunction and LC melanin loss at a similar level to diagnosed PD 
Commented [DB2]: Perhaps drop it altogether?! 
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patients. Third, our iRBD sample size of 22 was modest affecting our power to interrogate data 
statistically, particularly the neuromelanin and 11C-MeNER analyses. These cases, however, are 
not easy to find and recruit for complex imaging programmes. Fourth, since 11C-donepezil PET is 
not a specific parasympathetic marker, the significant intestinal 11C-donepezil signal reductions in 
iRBD may indicate both parasympathetic and local enteric nerve terminal damage.  
   In conclusion, iRBD patients display neuronal dysfunction in the peripheral autonomic nervous 
system and locus coeruleus equivalent to diagnosed PD patients although 71% of these iRBD 
patients have normal nigrostrial dopaminergic innervation. This pattern of dysfunction parallels 
Braak stage 2 -syn pathology in PD and supports the hypothesis that -syn misfolding and 
aggregation in iRBD,  a prodrome of both PD and DLB with RBD, initially targets terminals of the 
peripheral nervous system.  
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Figure Legends 
 
Figure 1. The five imaging modalities and their relationship to Braak stage structures are denoted by roman 
numerals. I. 11C-donepezil PET signal of the intestine is a surrogate marker of decreased cholinergic 
innervation, including parasympathetic innervation from the dorsal motor nucleus of the vagus (DMV). 
Arrows indicate the small intestine. 123I-MIBG is a validated tracer of sympathetic cardiac innervation II. 
11C-MeNER measures the density of noradrenergic terminals originating in the locus coeruleus (LC). The 
integrity of the pigmented cell bodies of the LC is estimated by neuromelanin-sensitive MRI (arrows). III. 
Striatal dopaminergic innervation from the substantia nigra (SN) is measured by 18F-DOPA PET. 
 
 
Figure 2. Representative images from healthy controls (HC), iRBD, and PD patients with the five imaging 
modalities. Individual cases are representative of the group mean within the respective groups. A. 11C-
donepezil PET/CT. Note lower donepezil uptake in the colon in iRBD and PD. Arrows denote transverse 
colon. B. 123I-MIBG scintigraphy of the heart (arrow). Note completely absent heart uptake in iRBD and 
PD. C. Neuromelanin (NM) MRI of locus coeruleus (arrows). Note lower locus coeruleus signal in iRBD 
and PD. D. 11C-MeNER PET. Thalamic MeNER binding potential (BPND), shown by arrows, is decreased 
in iRBD and PD. E. 18F-DOPA PET. Putamen FDOPA signal (arrows) is mildly decreased in some iRBD 
cases, but markedly decreased in PD. 
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Figure 3. A-B. The volume-corrected 11C-donepezil standard uptake values (SUV) in the small intestine 
(A) and colon (B) of healthy controls (HC), iRBD, and PD patients. The colon was impossible to define in 
one HC, leaving only 15 HC with colon values. C. Heart/mediastinum (H/M) ratio on the late 123I-MIBG 
images. D. Wash out values of MIBG from the early (15 min) to late image (3·5 h). [Solid lines denote 
group means. Dotted lines denote -1 and -2 SD below control mean].  
 
 
 
Figure 4. A. The MRI neuromelanin LC/pons ratio in healthy controls (HC), iRBD, and PD patients. B-C. 
The 11C-MeNER PET binding potential (BPND) in the thalamus (Th) and nucleus ruber (Ru). C. The 
minimum (left or right) 18F-DOPA Ki value in the putamen. [Solid lines denote group means. Dotted lines 
denote -1 and -2 SD below control mean]. 
 
 
Figure 5. The figure shows pathology indices (mean±SEM) of the present iRBD imaging data (black 
circles) listed according to Braak stage structures. For each imaging modality the healthy control (C) average 
is set at 0% and PD average at 100%. Grey circles show pathology indices from two previous MIBG 
studies19,31 (a & b), and two dopamine transporter SPECT studies32,33 (c & d). The four grey points in b show 
the MIBG pathology index of iRBD patients compared to H&Y stage I through IV PD patients (roman 
numerals: I, II, III, IV). Note that the H&Y I index was actually 300% (denoted by * and up-arrow). That 
particular MIBG study demonstrated that iRBD patients show more severe cardiac sympathetic denervation 
than H&Y I-II PD patients (MIBG index >100%). Similarly, our iRBD group showed a donepezil PET 
index of 157% when compared to our early stage PD patients. In one dopamine transporter SPECT studies, 
iRBD patients were compared to de novo H&Y I patients (c), and in another iRBD cases were compared to 
PD patients with and without RBD (depicted with + and - RBD). [DON: donepezil colon values, NM: 
neuromelanin MRI] 
 
